Tectonic Therapeutic Reports Positive Phase 1 Data for Rare Vascular Disease Drug
TX2100 cleared Phase 1a safety tests for HHT, a rare inherited vascular disorder with no approved treatments. FDA grants Fast Track status.
Tectonic Therapeutic announced Monday that its experimental drug TX2100 produced favorable safety, tolerability, and pharmacokinetic results in a Phase 1a clinical trial involving healthy adult volunteers, marking an early but meaningful milestone for a condition that currently has no approved therapies.
TX2100 is an investigational VHH-Fc fusion antagonist antibody designed to target the APJ, or apelin, receptor. The Watertown, Massachusetts-based biotechnology company is developing the drug as a potential treatment for Hereditary Hemorrhagic Telangiectasia, known as HHT, a rare inherited vascular disorder that causes abnormal blood vessel formation.
Read more Inland Empire Health Plan Marks 30 Years Serving Southern California →
The U.S. Food and Drug Administration granted TX2100 Fast Track Designation for HHT, a regulatory status intended to accelerate the development and review of drugs addressing serious conditions with unmet medical needs. The FDA separately cleared the company's Investigational New Drug application to proceed with a Phase 1b trial in HHT patients in the United States.
Tectonic Therapeutic, which trades on the Nasdaq under the ticker TECX, describes itself as a clinical-stage biotechnology firm focused on therapeutic proteins and antibodies that modulate G-protein coupled receptor activity. The Phase 1a trial was explicitly designed to support further clinical development of TX2100, and the IND clearance positions the company to begin enrolling actual HHT patients in the next trial phase.
Continue reading at GlobeNewswire - Industry News on Financial Services
